Superantigens and cystic fibrosis: Resistance of presenting cells to dexamethasone

Clinical and Diagnostic Laboratory Immunology

Volumn 7, Issue 4, 2000, Pages 553-556

  Ben Ari, Josef ^a,c   Gozal, David ^a   Dorio, Raymond J ^a   Bowman, C Michael ^a   Reiff, Andreas ^a   Walker, Sharyn M ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; EXOTOXIN; INTERLEUKIN 2; SUPERANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLAMMATION; LEUKEMIA CELL LINE; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; LYMPHOCYTE COOPERATION; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 0033910860     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.7.4.553-556.2000     Document Type: Article

References (35)

1. Armstrong, D. S., K. Grimwood, J. B. Carlin, R. Carzino, J. P. Gutierrez, J. Hull, A. Olinsky, E. M. Phelan, C. F. Robertson, and P. D. Phelan. 1997. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156:1197-1204.
2. Aubert, V., D. Schneeberger, A. Sauty, P. Sperisen, J. D. Aubert, and F. Spertini. 2000. Induction of tumor necrosis factor alpha and interleukin-8 gene expression in bronchial epithelial cells by toxic shock syndrome toxin 1. Infect. Immun. 68:120-124.
3. Auerbach, H. S., M. Williams, J. A. Kirkpatric, and H. R. Colten. 1985. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet ii:686-688.
4. Bisgaard, H., S. S. Pedersen, K. G. Nielsen, M. Skov, E. M. Laussen, G. Kronborg, N. Hoiby, and C. Koch. 1997. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 156:1190-1196.
5. Braun, C. M., S. K. Huang, G. G. Bashian, A. Kagley-Sobotka, L. M. Lichtenstein, and E. M. Essayan. 1997. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J. Allergy Clin. Immunol. 100:400-407.
6. Breslow, J. L., J. Epstein, J. H. Fontaine, and G. B. Forbes. 1978. Enhanced dexamethasone resistance in cystic fibrosis cells: potential use for heterozygote detection and prenatal diagnosis. Science 201:180-182.
7. Carlstedt-Duke, J., M. Bronnegard, and B. Strandvik. 1986. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. USA 83:9202-9206.
8. Distelhorst, C. W., B. M. Benutto, and J. M. Corry. 1983. Effect of mitogen concentration on glucocorticoid suppression of normal and cystic fibrosis lymphocyte activation. Cell. Immunol. 75:188-192.
9. Eigen, H., B. J. Rosenstein, S. FitzSimmons, and D. V. Schidlow. 1995. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J. Pediatr. 126:515-523.
10. Emilie, D., M. C. Crevon, R. Chicheportiche, M. T. Auffredou, R. Barot-Ciorbaru, G. Lenoir, J. M. Dayer, and P. Galanaud. 1990. Cystic fibrosis patients' B-lymphocyte response is resistant to the in vitro enhancing effect of corticosteroids. Eur. J. Clin. Invest. 20:620-626.
11. Fick, R. B., Jr. 1989. Pathogenesis of the pseudomonas lung lesion in cystic fibrosis. Chest 96:158-164.
12. Fujiki, M., T. Shinbori, M. Suga, H. Miyakawa, and M. Ando. 1999. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. Am. J. Respir. Cell. Mol. Biol. 21:675-683.
13. Fujisawa, N., S. Hayashi, A. Kurdowska, J. M. Noble, K. Naitoh, and E. J. Miller. 1998. Staphylococcal enterotoxin A-induccd injury of human lung endothelial cells and IL-8 accumulation are mediated by TNF-α. J. Immunol. 161:5627-5632.
14. Herman, A. J. W. Kappler, P. Marrack, and A. M. Pullen. 1991. Superantigens: mechanism of T-cell stimulation and role in immune responses. Ann. Rev. Immunol. 9:745-772.
15. Herz, U., R. Rückert, D. Wollenhaupt, T. Tschernig, U. Neuhaus-Steinmetz, R. Pabst, and H. Renz. 1999. Airway exposure to bacterial superantigen (SEB) induces lymphocyte-dependent airway inflammation associated with increased airway responsiveness - a model for non-allergic asthma. Eur. J. Immunol. 29:1021-1031.
16. Hofman, F. M., A. D. Wright, M. M. Dohadwala, F. Wong-Stall, and S. M. Walker. 1993. Exogenous tat protein activates human endothelial cells. Blood 82:2774-2780.
17. Hudson, V. L., C. L. Wielinski, and W. E. Regelmann. 1993. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J. Pediatr. 122:854-860.
18. Kammouni, W., C. Figarella, S. Marchand, and M. Merten. 1997. Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect. Immun. 65:5176-5183.
19. Konstan, M. W., P. J. Byard, C. L. Hoppel, and P. B. Davies. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332: 848-854.
20. Konty, E., M. Ziolkowska, A. Ryzewska, and W. Malinski. 1999. Protein kinase c-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6). Cytokine 11:839-848.
21. Langhoff, E., P. S. Pedersen, and C. Koch. 1984. Methylprednisolone resistance of cystic fibrosis lymphocytes. Pediatr. Res. 18:488-489.
22. Miller, E. J., A. B. Cohen, and B. T. Peterson. 1996. Peptide inhibitor of interleukin-8 (IL-8) reduces staphylococcal enterotoxin-A (SEA) induced neutrophil trafficking to the lung. Inflamm. Res. 45:393-397.
23. Neumann, B., K. Emmanuilidis, M. Stadler, and B. Holzmann. 1998. Distinct functions of interferon-gamma for chemokine expression in models of acute lung inflammation. Immunology 95:512-521.
24. Osusky, R., R. J. Dorio, Y. K. Arora, S. J. Ryan and S. M. Walker. 1997. MHC class II positive retinal pigment epithelial (RPE) cells can function as antigen-presenting cells for microbial superantigen. Occular Immunol. Inflam. 5:43-50.
25. Ray, A., S. LaForge, and P. B. Sehgal. 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol. Cell. Biol. 10: 5736-5746.
26. Rosenstein, B. J., and H. Eigen. 1991. Risk of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 87:245-246.
27. Schuster, A., A. Haarmann, and V. Wahn. 1995. Cytokines in neutrophil-dominated airway inflammation in patients with cystic fibrosis. Eur. Arch. Oto-Rhino-Laryng. 1(Suppl.):S59-S60.
28. Schwiebert, E. M., D. J. Benos, M. E. Egan, M. J. Stutts, and W. B. Guggino. 1999. CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 79(Suppl. 1):S145-S166.
29. Shimizu, T., C. Hansson, and B. Strandvik. 1994. Defective inhibition by dexamethasone of leukotriene B4 and C4 production by leukocytes in patients with cystic fibrosis. Prostaglandins Leukotrienes Essen. Fatty Acids 51:407-410.
30. Snyder, D. S., and E. R. Unanue. 1982. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J. Immunol. 129:1803-1805.
31. Sugden, B. 1989. An intricate route to immortality. Cell 57:5-7.
32. Tabary, O., J. M. Zahm, J. Hinnrasky, J. P. Couetil, P. Cornillet, M. Guenounou, D. Gaillard, E. Puchelle, and J. Jacquot. 1998. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am. J. Pathol. 153:921-930.
33. Takei, S., Y. Arora, and S. M. Walker. 1993. Intravenous immunoglobulin contains antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91:602-607.
34. van Seventer, G. A., W. Newman, Y. Shimizu, T. B. Nutman, Y. Tanaka, K. J. Horgan, T. V. Gopal, E. Ennis, D. O'Sullivan, H. Grey, and S. Shaw. 1991. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J. Exp. Med. 174:901-913.
35. Weiss, A., R. Shields, M. Newton, B. Manger, and J. Imboden. 1987 Ligand-receptor interactions required for commitment to the activation of the interleukin-2 gene. J. Immunol. 138:2169-2178.